Objective: The purpose of this study was to determine if folic acid supplementation improves endothelial vascular function (brachial artery flow-mediated dilation; FMD) in amenorrheic runners.
INTRODUCTION
Many women enjoy the benefits of a healthy active lifestyle, including running. As the number of women running and participating in sports increases, so does the prevalence of serious exercise-associated menstrual irregularities. Low estrogen levels found in postmenopausal women is very similar to the steroid hormonal profile found in athletic amenorrhea. As soon as 7 days after ovariectomy in premenopausal women 1 and 3 months after menopause, 2 reduced brachial artery endothelium-dependent vasodilatation can be seen. Endothelial dysfunction is a precursor to all coronary risk factors and leads to the development of coronary artery disease (CAD), chronic heart failure, and the presence of a generalized inflammatory response. 3 Endothelial dysfunction is likely the sentinel atherogenic event [4] [5] [6] and earliest sign of cardiovascular disease. 2 This is of great concern because cardiovascular disease is the number one cause of death in women.
Researchers have found that young female runners with athletic amenorrhea have significantly reduced endotheliumdependent flow-mediated dilation (FMD) of the brachial artery when compared with eumenorrheic runners. [7] [8] [9] Brachial artery endothelial dysfunction (FMD, 1.10% 6 0.96%) in these young women (age, 21.9 6 1.2 years, mean 6 SD) [7] [8] [9] were similar to significantly older women (age, 60.0 6 2.0 years) with established cardiovascular disease. 10 Previous studies have shown that oral contraceptive pills (estrogen and progesterone components) can improve brachial artery FMD in amenorrheic women. 8 However, in light of the Women's Health Initiative 11 that revealed an added cardiovascular risk with hormone therapy, alternative therapy must be considered. One such therapy to consider is folic acid.
Folic acid has been found to improve endotheliumdependent vasodilatation in men with hypertension, CAD, congestive heart failure, and peripheral vascular disease. [12] [13] [14] Recently, a study has shown that folic acid supplementation (10 mg/d) improves brachial artery FMD in eumenorrheic women runners with normal folic acid levels when compared with a placebo control group. 15 Therefore, the purpose of this study was to determine if 4 weeks of folic acid supplementation (10 mg/d) would improve brachial artery FMD to a greater extent in amenorrheic runners with normal serum folate levels.
METHODS

Subjects and Experimental Design
Subjects were recruited via advertisements (flyers and newspapers), physician referrals, and established relationships with subjects. In addition, subjects were recruited from local colleges and running clubs. All protocols were approved by the institutional review board committee at our institution.
Inclusion criteria consisted of healthy women aged 18 to 35 years with no medical conditions, running at least 20 miles per week for the past 12 months. The amenorrheic group was defined as having the presence of primary amenorrhea (absence of menses by age 15) or secondary amenorrhea (absence of 3 or more consecutive menstrual cycles after menarche). The eumenorrheic group was defined as having the menstrual bleeding every 26 to 32 days for at least 12 months; however, determining ovulation for the eumenorrheic group was beyond the scope of this study.
Subjects were excluded from the study if they were pregnant, hypertensive, on birth control pills or hormone replacement therapy, or smokers. Subjects were also excluded if they had a known pituitary tumor, anorexia nervosa, thyroid disorder, diabetes mellitus, chromosomal abnormality, hypercoagulable state, hypercholesterolemia, or history of cardiovascular disease. Subjects were not excluded on the basis of race; however, all the participants in this study were of white ethnicity. Three subjects in the amenorrheic group were eliminated; 1 met criteria for anorexia nervosa, 1 ran significantly more than the other subjects (65 miles/wk), and 1 did not complete a full 4 weeks of folic acid supplementation. Therefore, only 7 athletic amenorrheic subjects were available for study purposes.
Twenty women gave written informed consent in accordance with our institutional review board (10 amenorrheic and 10 eumenorrheic women). All subjects filled out questionnaires about their health and menstrual status and reported miles run per week. No subjects had a family history of cardiovascular disease. Many of the study participants reported taking a multivitamin (n = 9 in the amenorrheic group and n = 8 in the eumenorrheic group). Subjects received 10 mg/d of folic acid daily in both groups for 4 weeks. The eumenorrheic participants were studied during the follicular phase of their menstrual cycle (days 4-8) because it is known that brachial artery FMD varies during the menstrual cycle in relation to both estrogen and progesterone levels. [16] [17] [18] All subjects had their brachial artery FMD remeasured after 4 weeks of folic acid supplementation. Subjects were studied in the morning after an overnight fast.
Serum Folic Acid Levels
Fasting whole serum folate levels were measured by the Bayer ADVIA Centaur assay (Siemens Medical Solutions Diagnostics, Deerfield, Illinois) before and after supplementation with folic acid. This assay is a competitive immunoassay using direct chemiluminescent technology. The interassay coefficient of variation was 5% to 7%, the intra-assay coefficient of variation was 4% to 8%, the lower limit of sensitivity was 0.35 ng/mL, and the upper limit of sensitivity was .24 ng/mL.
Endothelial Function
All subjects underwent brachial artery FMD testing at baseline and after 4 weeks of folic acid supplementation in the same arm. Brachial artery FMD was measured using the same ultrasound technique as previous studies done in this laboratory and those done by Celermajer et al. 4, 10 This brachial artery technique was found to have a reproducibility coefficient of variation of 1.4% and a repeatability coefficient of variation of 2.3%. Subjects were instrumented for continuous recording of electrocardiogram (lead II), heart rate, capillary oxygen saturation, and intermittent blood pressure using an automated cuff. Brachial artery FMD was measured as follows: in the supine position with the nondominant arm in a comfortable position, and a sphygmomanometric cuff was placed around the forearm distal to the antecubital fossa. 19, 20 An ultrasound machine, using a 10 MHz linear array small footprint probe (intraoperative), was secured over the brachial artery. Images of the brachial artery were made along the longitudinal axis after identifying a .5 cm segment where the near and far endothelial borders were clearly delineated. The ultrasound probe was used to measure both vessel diameter and blood flow velocity using the pulsed Doppler mode. The electrocardiogram was recorded simultaneously with the ultrasound image to gate events in the cardiac cycle. At least 15 seconds of stable diameter recordings were assessed at each point where data were acquired. All brachial artery images were recorded for subsequent analysis. Image analysis was performed on a dedicated Pentium IV computer using a Matrox millennium card (Matrox Electronic Systems Dorval, Quebec, Canada) for analog-to-digital conversion of analog images at high resolution. Diameter was measured from digitized images using an automated edge detection program (Brachial Analyzer and Brachial Imager) from Medical Imaging Systems (Iowa City, Iowa). Ten images were obtained each second for 10 seconds, and the average minimum diameter for each cardiac cycle was used for analysis. To minimize variation, 1 experienced operator blinded to menstrual status performed all investigations.
Endothelium-dependent FMD was quantified as the peak percent change in diameter of the brachial artery from resting baseline (at end diastole) to reactive hyperemia, where measurements were made at 30 seconds, 1 minute, and 2 minutes after release of a 4.5 minute forearm occlusion (cuff inflation to 40 mmHg above systolic pressure). Brachial artery blood flow velocity was measured as the peak systolic velocity from the pulsed wave velocity signal, which was corrected for probe angulations with respect to the vessel. The hyperemic response was measured as the percent change from baseline to the point of maximal reactive hyperemia after release of the forearm cuff occlusion.
Statistical Analysis
Descriptive statistics are presented as means and SD for each measure at baseline and after 4 weeks of folic acid supplementation. Approximation to the Wilcoxon rank-sum test was used to compare the 2 groups at baseline and after folic acid supplementation. The primary outcome of interest for this study was comparing the 4-week change in brachial artery vasodilator response to reactive hyperemia between both groups. For this, we compared the change in the FMD using the approximation with the Wilcoxon rank-sum test.
RESULTS
Baseline characteristics of the amenorrheic and eumenorrheic groups are presented in Table 1 . There were no differences between the groups in age, height, age of menarche, use of multivitamins, or miles run per week. All subjects had an evidence of secondary amenorrhea.
The brachial artery parameters before folic acid supplementation are described in Table 2 . The baseline heart rates and blood pressures were similar between the folic acid and placebo groups ( Table 2 ). The 2 groups had similar serum folate levels both before and after supplementation ( Table 3) . Of note, our laboratory reports a value of ''.24'' for all values greater than 24 (ie, 26, 28, 30, and 100). Therefore, the actual serum folate level may actually be higher than reported.
The brachial artery parameters after folic acid supplementation are described in Table 4 . The brachial artery FMD response to reactive hyperemia improved after folic acid supplementation in amenorrheic women when compared with their pretreatment baseline (3.0% 6 2.3% vs. 7.7% 6 4.5%; P = 0.02) (Figure 1 ). In the eumenorrheic control group, the baseline brachial artery FMD and posttreatment brachial artery FMD were similar (6.7% 6 2.0% vs. 5.9% 6 2.6%; P = 0.52) ( Figure 1 ). The change in the brachial artery FMD between the baseline and after folic acid supplementation of the 2 groups was significant (4.7 6 4.1 vs. 20.7 6 3.5; P = 0.02) ( Table 5 ). In addition, there was a difference between the amenorrheic and eumenorrheic brachial artery FMD values at baseline (3.0% 6 2.3% vs. 6.7% 62.0%; P = 0.01) ( Table 5) , which was not present after folic acid supplementation (7.7% 6 4.5% vs. 5.9% 6 2.6%; P = 0.35) ( Table 5 ).
DISCUSSION
In this prospective cross-sectional study, we found that 4 weeks of folic acid supplementation improved brachial artery FMD in amenorrheic runners. Folic acid supplementation has already been shown in several studies to improve endothelial function in various disease states, including hypercholesterolemia, 13 ,21 hypertension, 22 diabetes, 23 and CAD. 24, 25 These studies suggest that higher folic acid intake (much larger than daily recommended levels) by specific populations may have vasculoprotective effects. Before amenorrheic female runners can be added to this group, a large cohort study followed for several years needs to be performed.
Rickenlund et al 8 have shown that oral contraceptive administration (30 mg ethinyl estradiol and 150 mg levonorgestrel) significantly improved brachial artery FMD in young amenorrheic runners. However, the Women's Health Initiative study showed an increased risk of breast cancer, heart disease, stroke, and blood clots among postmenopausal women who were using hormone replacement therapy that included both estrogen and progestin. 11, 26 Although our subjects are not postmenopausal, an alternative treatment approach to reduced brachial artery FMD in amenorrheic runners needs to be explored.
Folic acid has potential benefits with regards to cardiovascular parameters such as endothelial function, arterial stiffness, blood pressure, and thrombotic activity. 22, [27] [28] [29] [30] [31] [32] [33] [34] There are several mechanisms to explain the effectiveness of folic acid therapy. Folates are thought to participate in the endogenous regeneration of tetrahydrobiopterin, 35 an essential cofactor for endothelial nitric oxide synthase (eNOS) production of nitric oxide, and therefore may result in increased NO production after supplementation. Nitric oxide is solely responsible for flow-induced dilation of the brachial artery in humans. Folic acid has a known homocysteine-lowering effect that could contribute to improvements in endothelial function. 36, 37 Finally, folic acid may have a direct antioxidant effect in the vasculature, increasing NO bioavailability and improving FMD. 38 Folic acid has been shown to be beneficial for cardiovascular parameters; however, the optimal dose is unknown. Folic acid supplementation at 10 mg daily has been used in other studies, which have shown that it is safe and it improves FMD (Table 6) . 14, 39, 40, 43, 44 We have recently shown that folic acid supplementation (10 mg/d) for 4 to 6 weeks significantly improved endothelium-dependent FMD in eumenorrheic women runners with normal folic acid levels when compared with a placebo control group. 15 In that study, the 6-week change in brachial artery vasodilator response to reactive hyperemia was significantly greater (P , 0.01) in eumenorrheic runners with folic acid supplementation (3.5% 6 0.6%) compared with the placebo group (0.1% 6 0.2%). 15 When comparing FMD for the eumenorrheic group in this study and our previous study, baseline FMD was similar at 6.7% and 6.6%, respectively. Folic acid levels were also similar at baseline 17.4 ng/mL and 19.9 ng/mL, respectively. However, follow-up folic acid levels are difficult to quantify because our laboratory only goes up to 24 ng/mL. Therefore, the eumenorrheic group in the previous study could have had a significantly higher folic acid level than the current study, but we were unable to quantify this.
There have been no reported side effects of folic acid at 10 mg/d, 14, 39, 40, 43, 44 and the Food and Drug Administration's MedWatch system does not list any adverse effects of folic acid that apply to this study. 44 Higher doses . 15 mg/d can cause side effects such as upset stomach, sleep disturbances, and skin problems. The recommended daily allowance for folate for women aged 19 to 50 years is 400 mg/d, and the tolerable upper intake level is 1 g/d. For women with risk factors for neural tube defects, 4 mg is recommended. It is important to recognize that the upper intake level refers to the amount of synthetic folate (folic acid) being consumed per day from fortified foods and/or supplements. There is no health risk and no upper intake level for natural sources of folate found in food. The risk of toxicity from folic acid intake from supplements and/or fortified foods is low. 45 It is a water-soluble vitamin that is regularly eliminated in the urine. Folic acid has shown benefit in cardiovascular disease, Alzheimer disease, and the prevention of colon cancer and neural tube defects. 46 Despite the benefits of folic acid, there is some evidence that high levels of folic acid can pose a variety of health risks. High doses of folic acid can provoke seizures in patients taking anticonvulsant medications. 47 None of our subjects had a known seizure disorder. The National Institutes of Health 48 also states that under supplementation with folic acid, caution should be used in patients with a vitamin B12 deficiency as this may hide the deficiency and silently exacerbate the condition. None of our subjects had a known vitamin B12 deficiency. A recent study raises the possibility that folic acid supplementation might increase the risk of colorectal adenoma in patients with a known history of colorectal adenomas. 49 In this study, the rates of colon cancer reoccurrences were slightly higher at the first and second colonoscopic follow-ups (44.1% and 41.9%, respectively) when compared with the placebo control group (42.4% and 37.2%, respectively). This small-observed increase may be related to more widespread screening and better detection. Evidence linking folic acid supplementation and an increase in colon cancer rates is inconclusive and merits further investigation. Folic acid has Hyperhomocysteinemia not been shown to directly cause colon cancer; however, if colon cancer is present, folic acid may fuel its growth. 49 The risks of folic acid supplementation are small and may be inconclusive in regards to increased colon cancer risk. In many patient populations, the benefits of folic acid supplementation likely outweigh the risks. From a clinical perspective, it would seem logical that if brachial artery FMD was determined to be low, clinicians could potentially recommend folic acid on a daily basis to amenorrheic runners. However, the optimal dose is still to be determined.
Although the current results are significant for the amenorrheic group, there are several limitations to this study. Both the amenorrheic and eumenorrheic groups contained small numbers of subject; therefore, these observations should be investigated in a larger cohort of individuals. Folic acid was taken only for 4 weeks, which may not be a long enough duration for the optimal benefit. Furthermore, despite not obtaining extensive dietary histories or controlling for other folic acid intake, the serum folate levels were higher after folic acid supplementation, likely confirming our assumption that the 10 mg/d supplementation was the major factor influencing the brachial artery FMD improvement in the amenorrheic group.
CONCLUSIONS
Our data indicate that oral folic acid treatment may provide a safe and inexpensive tool to improve brachial artery FMD in amenorrheic female runners. The present observation may have important clinical implications particularly for athletes opposed to estrogen supplementation. Further research is needed to determine the lowest optimal dose of folic acid at which significant vascular benefit occurs.
